Needham & Company Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD) on ACP-044 Failure, Sees Minimal Impact, "Wouldn't Be Surprised if the Stock Bounces"
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD), following the company's announcement of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
